Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,716.00
(
0.28%
)
News Focus
News Focus
Post# of 257267
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Katsche post# 171263

Friday, 12/13/2013 4:45:06 AM

Friday, December 13, 2013 4:45:06 AM

Post# of 257267

ABBV/ENTA—Therefore, the SVR12 for GT1b naive for Pearl III (450+267+333) must be between 95-98%. The figures for GT1b [treatment-experienced] (Pearl II) must be between 90% and 97%.

Are you referring to the ribavirin arms or the non-ribavirin arms of PEARL-2 and PEARL-3? The purpose of these two trials is to find out if ribavirin is needed in TE GT1b and TN GT1b, respectively (#msg-94927196).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today